Aimee S Weisner
CIK 1227308 · CVP, General Counsel · last filed 2026-06-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
GKOS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
IRVINE, CA 92614
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GKOS | Director | 22,684 | $181.43 | $4.12M | -$4.67M | 26 | 2026-06-23 |
| LNSR | Director | 110,368 | $5.97 | $658.9K | $131.3K | 10 | 2026-06-05 |
| STAA | Director | 15,352 | $23.69 | $363.7K | $164.1K | 7 | 2024-06-24 |
| Oyster Point Pharma, Inc. (OYST) Delisted | Director | 3,573 | $11.17 | $39.9K | $0 | 5 | 2023-01-04 |
| EW | CVP, General Counsel | 10,050 | $90.39 | $908.4K | $0 | 3 | 2012-05-11 |
Recent Filings · Page 4 of 7
61 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-06-06 | GKOS | Grant (A) | +4,364 | $0 | EDGAR |
| 2022-05-27 | LNSR | Grant (A) | +4,285 | $0 | EDGAR |
| 2022-01-05 | GKOS | Grant (A) | +1,455 | $0 | EDGAR |
| 2021-08-09 | GKOS | Grant (A) | +2,000 | $103.3K | EDGAR |
| 2021-06-09 | Oyster Point Pharma, Inc. (OYST) Delisted | Grant (A) | +3,466 | $0 | EDGAR |
| 2021-06-07 | GKOS | Grant (A) | +2,382 | $0 | EDGAR |
| 2021-05-20 | LNSR | Grant (A) | — | $0 | EDGAR |
| 2021-03-16 | LNSR | Grant (A) | — | $0 | EDGAR |
| 2021-02-02 | LNSR | Grant (A) | — | $0 | EDGAR |
| 2021-01-06 | GKOS | Grant (A) | +980 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.